{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:30:45Z","timestamp":1783625445781,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.tox.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T17:01:41Z","timestamp":1489683701000},"page":"24-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity"],"prefix":"10.1016","volume":"382","author":[{"given":"Tara P.","family":"Chambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Santiesteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2017.03.006_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1056-8719(97)00033-6","article-title":"Morphological and biochemical characterization and analysis of apoptosis","volume":"37","author":"Allen","year":"1997","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tox.2017.03.006_bib0010","doi-asserted-by":"crossref","first-page":"10244","DOI":"10.1074\/jbc.M112355200","article-title":"Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes","volume":"277","author":"Aoki","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2017.03.006_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.tox.2017.03.006_bib0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate At two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: s0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tox.2017.03.006_bib0025","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tox.2017.03.006_bib0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12012-012-9177-8","article-title":"Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts","volume":"12","author":"Branco","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.tox.2017.03.006_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing mitochondrial dysfunction in cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.tox.2017.03.006_bib0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jcb.20563","article-title":"Amplification loop cascade for increasing caspase activity induced by docetaxel","volume":"96","author":"Cao","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tox.2017.03.006_bib0045","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.1074\/jbc.M111.223602","article-title":"Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation","volume":"286","author":"Chambers","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2017.03.006_bib0050","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1021\/cb200062a","article-title":"Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1 (KIM1)","volume":"6","author":"Chambers","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tox.2017.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1074\/jbc.M112.421354","article-title":"Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo","volume":"288","author":"Chambers","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2017.03.006_bib0060","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1074\/jbc.M112.406777","article-title":"Inhibition of JNK mitochondrial localization and signaling is protective against ischemia\/reperfusion injury in rats","volume":"288","author":"Chambers","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2017.03.006_bib0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbrc.2015.05.075","article-title":"Sub-chronic administration of LY294002 sensitizes cervical cancer cells to chemotherapy by enhancing mitochondrial JNK signaling","volume":"463","author":"Chambers","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tox.2017.03.006_bib0070","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tox.2017.03.006_bib0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbrc.2004.04.148","article-title":"Phosphorylation of the mitochondrial protein Sab by stress-activated protein kinase 3","volume":"319","author":"Court","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tox.2017.03.006_bib0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"DeMatteo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2017.03.006_bib0090","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tox.2017.03.006_bib0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1538-7836.2005.01781.x","article-title":"In-Cell Western assay: a new approach to visualize tissue factor in human monocytes","volume":"4","author":"Egorina","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.tox.2017.03.006_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0105","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.ejca.2006.03.029","volume":"42","author":"Glabbeke","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tox.2017.03.006_bib0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.cdd.4401231","article-title":"Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis","volume":"10","author":"Gottlieb","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tox.2017.03.006_bib0115","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","article-title":"Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy","volume":"44","author":"Grazette","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tox.2017.03.006_bib0120","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1074\/jbc.M708916200","article-title":"Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury","volume":"283","author":"Hanawa","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2017.03.006_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.tox.2017.03.006_bib0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.cdd.4400572","article-title":"Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia","volume":"6","author":"He","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tox.2017.03.006_bib0135","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0192623311419524","article-title":"A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat","volume":"39","author":"Herman","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.tox.2017.03.006_bib0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tox.2017.03.006_bib0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tox.2017.03.006_bib0150","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/toxsci\/kfs192","article-title":"Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase","volume":"129","author":"Hu","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2017.03.006_bib0155","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.tox.2017.03.006_bib0160","series-title":"Methods in Cell Biology","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-679X(06)80014-2","article-title":"Imaging of mitochondrial polarization and depolarization with cationic fluorophores","author":"Lemasters","year":"2007"},{"key":"10.1016\/j.tox.2017.03.006_bib0165","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tox.2017.03.006_bib0170","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0046-8177(99)90040-0","article-title":"Gastrointestinal stromal tumors: recent advances in understanding of their biology","volume":"30","author":"Miettinen","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tox.2017.03.006_bib0175","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-Phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.tox.2017.03.006_bib0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/annonc\/mdm468","article-title":"Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity","volume":"19","author":"Perik","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tox.2017.03.006_bib0185","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11010-012-1252-8","article-title":"BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases","volume":"365","author":"Sarszegi","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.tox.2017.03.006_bib0195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.0000202487.68969.f7","article-title":"Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats","volume":"47","author":"Schellings","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.tox.2017.03.006_bib0200","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-05-3906","article-title":"Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms","volume":"66","author":"Tarn","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2017.03.006_bib0210","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.24683","article-title":"Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate","volume":"116","author":"Trent","year":"2010","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2017.03.006_bib0215","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.leukres.2003.10.005","article-title":"Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era","volume":"28","author":"Van Etten","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0220","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analyis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tox.2017.03.006_bib0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","article-title":"Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells","volume":"106","author":"Will","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2017.03.006_bib0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj20020553","article-title":"A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria","volume":"367","author":"Wiltshire","year":"2002","journal-title":"Biochem. J"},{"key":"10.1016\/j.tox.2017.03.006_bib0235","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1038\/cddis.2013.522","article-title":"JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death","volume":"5","author":"Win","year":"2014","journal-title":"Cell. Death. Dis."},{"key":"10.1016\/j.tox.2017.03.006_bib0240","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.28486","article-title":"c-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src","volume":"63","author":"Win","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2017.03.006_bib0245","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tox.2017.03.006_bib0250","doi-asserted-by":"crossref","first-page":"C125","DOI":"10.1152\/ajpcell.00247.2006","article-title":"Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells","volume":"292","author":"Wu","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tox.2017.03.006_bib0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/abio.2002.5698","article-title":"A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP","volume":"306","author":"Yang","year":"2002","journal-title":"Anal. Biochem."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X17300768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X17300768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:34:34Z","timestamp":1759534474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X17300768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":51,"alternative-id":["S0300483X17300768"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2017.03.006","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}